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ABSTRACT Bullous pemphigoid (BP) has been associated with 
neurological disorders (NDs), which has led to the hypothesis that 
molecular mimicry exists between hemidesmosomal proteins and 
neuronal peptides. A 79-year-old hemiparetic woman presented 
with tense bullae affecting exclusively her right paretic upper limb 
for three months. Histopathology, taken from the perilesional area, 
revealed an inflammatory infiltrate with predominant eosinophils. 
IIF evidenced linear IgG deposition in the epidermal side of the 
cleavage. ELISA detected circulating anti-BP180 and anti-BP230 
autoantibodies. Immunoblotting exhibited unspecific reactivity 
against the 190-kDa periplakin in normal human epidermal extract. 
The immunocompromised cutaneous district concept may explain 
the possible mechanism for the exclusive involvement of the auto-
immune blistering disease in lymphedematous hemiparetic upper 
limb.
KEY WORDS: bullous pemphigoid, stroke, vascular dementia, 
hemiplegia.
INTRODUCTION
Bullous pemphigoid (BP) is caused by autoanti-
bodies that act against the BP180 (XVII collagen) and 
BP230 (dystonin) hemidesmosomal proteins (1). BP 
has been reported to be associated with neurologi-
cal disorders (NDs) – the homology between the BP 
antigens in the skin and the neuronal peptides in the 
central nervous system has been proposed as a pos-
sible cause for the association between BP and NDs 
(2, 3). Dementia and cerebrovascular accident are the 
main NDs associated with BP (4). 
In 1992, Long et al. (5) reported on the first case of 
unilateral BP involvement in a patient with hemipa-
resis. The pathogenesis of preferential bullous forma-
tion on the hemiparetic side remains unclear, but Pic-
colo et al. (6) have proposed the explanation of this 
relation with a novel immunocompromised cutane-
ous district concept.
This report describes a BP patient with exclusive 
involvement of the paretic upper limb, developed 
after ischemic cerebrovascular accident followed by 
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vascular dementia, who responded well to treatment 
with Dapsone.
CASE REPORT
A 79-year-old hemiparetic female wheelchair 
user presented with tense bullae that had developed 
three months previously and exclusively affected the 
right paretic upper limb. She had a history of three 
ischemic cerebrovascular accidents due to bilateral 
carotid stenosis. The last event had occurred three 
years previously and resulted in right hemiparesis, 
aphasia, and seizure events, besides diagnosis of 
vascular dementia stage 3 as determined by Clinical 
Dementia Rating during geriatric evaluation. She also 
presented hypertension, dyslipidemia, glucose intol-
erance, and gastrointestinal bleeding episodes due to 
gastric angiodysplasia. At the onset of the blistering 
lesions, there had been no particular change in the 
regular medications used to treat her comorbidities, 
namely atenolol 100 mg, phenytoin 100 mg twice a 
day, aspirin 100 mg, atorvastatin 20 mg, furosemide 
40 mg, and ranitidine 40mg.
Physical examination revealed multiple tense bul-
lae with hyaline or purulent content as well as ero-
sions and crusts on the right upper limb, particularly 
on the forearm and on the hand dorsum and palm. 
Inflammatory signs with pronounced erythema and 
swelling resembling streptococcal erysipelas were 
also detected. Interestingly, the bullous lesions only 
affected the paretic upper limb (Figure 1, A). The le-
sion did not involve mucosal surfaces. A swab of the 
blistering lesion evidenced Staphylococcus aureus 
and Staphylococcus epidermidis. Based on the antibio-
gram, the patient was prescribed cephalexin 500 mg 
Figure 1. (A) Multiple tense bullae with hyaline or purulent content, erosions and hematic crusts, and erythema and intense 
swelling in the paretic right upper limb. (B) Histopathology of the skin revealed an inflammatory infiltrate where eosinophils 
predominated in the upper dermis and eosinophilic spongiosis emerged in the epidermis (Hematoxylin-eosin, ×400). (C) 
Indirect immunofluorescence using human skin as substrate (NaCl-salt split skin) and serum dilution 1:20 evidenced linear 
IgG fluorescence in the epidermal side of the cleavage (×400). The slide was counter-colored with Evan’s blue (red color). (D) 
Immunoblotting using normal human epidermal extract showed an unspecific reactivity against the 190-kDa periplakin. (E) 
Right upper limb four months after treatment with dapsone was discontinued; the residual lymphedema can be attributed 
to hemiparesis. 




every six hours, followed by sulfamethoxazole-and-
trimethoprim 800/160 mg twice a day for 14 days 
while the laboratorial tests were being processed.
Laboratory tests showed hypertriglyceridemia 
(240 mg/dL; normal <150 mg/dL) and slightly in-
creased carcinoembryonic antigen (2.79 ng/mL; 
normal <2.5 ng/ml). Blood counts, renal function, 
electrolytes, blood calcium, total cholesterol, and gly-
cemic levels were within the normal range. Serology 
for hepatitis B and C, HIV, and VDRL were negative. 
The results obtained for the G6PD test, blood pro-
teins, and cancer antigen-125 were within the normal 
range. Transvaginal ultrasound, colonoscopy, chest 
X-ray, and mammography did not reveal any abnor-
mality.
A skin biopsy was taken from the perilesional 
area. Histopathology evidenced an inflammatory in-
filtrate where eosinophils predominated in the upper 
dermis, and eosinophilic spongiosis emerged in the 
epidermis (Figure 1, B). Linear IgG in the basal mem-
brane zone (BMZ) was documented by direct immu-
nofluorescence. Indirect immunofluorescence (IIF) 
based on 1M-NaCl-split normal human skin as a sub-
strate showed linear IgG fluorescence in the epider-
mal side of the cleavage (Figure 1, C). Complement 
IIF, detected using anti C3 secondary antibody, was 
negative at the titer of 1:20. Immunoblotting of nor-
mal human epidermal extract exhibited an unspecific 
reactivity against the 190-kDa periplakin (Figure 1, D). 
No positive reactivity arose during immunoblotting 
using other antigen sources, including recombinant 
proteins of NC16a and C-terminal domains of BP180, 
concentrated culture supernatant of HaCaT cells, and 
purified human laminin 332 (laminin 5) (data not 
shown). ELISA (MBL, Nagoya, Japan) resulted in posi-
tive serology for both BP230 (index 37.3U/L, cut off 9) 
and BP180 (index 18.0U/L, cut off 9), but negativity 
for both desmoglein (Dsg) 1 and Dsg 3 (index 0.845U/
L and 0.443U/L, respectively; cut off 12). 
The antibiotics improved the clinical course but 
bullae recurred later. Therefore, the patient was pre-
scribed Dapsone 50 mg per day. Remission of BP le-
sions was achieved four months after the treatment, 
so the Dapsone dose was reduced to 50 mg on alter-
nate days and suspended four months after the last 
active lesion was detected. Stable remission contin-
ued three years after the drug was discontinued (Fig-
ure 1, E).
This study was approved by the local Research Eth-
ics Committee approved this study (#051174/2015), 
and the patient provided the informed consent. 
DISCUSSION
This case report involves topics that deserve dis-
cussion: exclusive localization of the BP blistering le-
sions on the hemiparetic limb, association between 
BP and NDs, and the immunocompromised cutane-
ous district concept.
Remarkably, the blistering lesions were distrib-
uted exclusively in the upper hemiparetic limb. To 
our knowledge, this is the eighth case that has shown 
this distribution form (5, 7-9). Decreased blood flow, 
impaired nerve function, muscle contraction, adverse 
effects of ND medications, immobility, and scratching 
of the affected area are factors that may explain the 
unilateral compromise of BP in hemiparetic patients 
(7).
This patient presented blistering BP lesions three 
years after the third ischemic cerebrovascular acci-
dent, associated with vascular dementia. Association 
between BP and NDs has been increasingly reported 
(4). Both the expression of BP180 in the human brain 
tissue and the presence of a neural BPAG1n type, fa-
vor a possible molecular mimicry between BP anti-
gens and neuronal peptides (2, 3).
In contrast to the case reported by Tsuruta et al. 
(7), who reported minimum inflammatory cells, the 
histopathological findings obtained for our patient 
showed that an eosinophilic inflammatory infiltrate 
predominated in the upper dermis, allied to eosino-
philic spongiosis in the epidermis. 
Despite oral or topical corticosteroids as a thera-
peutic option in this case, due to local damage and 
residual lesions by previous infection it was decided 
to initiate Dapsone, which has been successfully used 
in the treatment of BP (10).
Finally, the immunocompromised cutaneous dis-
trict concept proposed by Ruocco et al. (2009) (11) 
considers that an injured cutaneous site, such as the 
lymphedematous paretic limb in this case, may be-
come a privileged location for opportunistic infec-
tions, tumors, and immune reactions. 
CONCLUSION
BP is characterized clinically by tense bullae, main-
ly distributed on the extremities and the trunk. In this 
case we described a very unusual condition where 
BP lesions appeared exclusively in a hemiparetic limb 
and nowhere else. The pathological mechanisms 
involved in this condition have not been fully eluci-
dated. The immunocompromised cutaneous district 
concept considered that chronic lymphedema might 
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generate local immune reactions and/or molecular 
aggressions to hemidesmossomal proteins, which 
may trigger BP exclusively in the lymphedematous 
hemiparetic upper limb.
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